Date | Source | Rubrik | Type | Alternative |
---|---|---|---|---|
2024-04-26 | Orexo | Report from Orexo AB's annual general meeting, 26 April 2024 | Pressreleaser | Download | Show Close |
Pressreleaser |
Report from Orexo AB’s annual general meeting, 26 April 2024Election of the board of directors and auditor The annual general meeting in Orexo AB (publ) on 26 April 2024 resolved, in accordance with the nomination committee’s proposal, that the number of board members shall be five with no deputy board members. James Noble, Staffan Lindstrand, Fred Wilkinson, Christine Rankin and Robin Evers were re-elected as ordinary board members. James Noble was elected as chairman of the board. Ernst & Young Aktiebolag was re-elected as auditor. Fees to the board of directors and the auditor The annual general meeting also resolved on fees to the board of directors in accordance with the nomination committee’s proposal. The fees to the board of directors shall amount to SEK 2,650,000 to be allocated as follows: SEK 900,000 to the chairman and SEK 300,000 to each of the other board members, and in total SEK 400,000 to be allocated to the members of the audit committee so that the chairman of the committee receives SEK 200,000 and SEK 200,000 are allocated in equal parts between the other members of the committee, and in total 150,000 to be allocated to the members of the remuneration committee in equal parts between the members of the committee, and that fees to the auditor shall be paid against approved accounts. Further, the annual general meeting resolved on an additional board fee in accordance with the nomination committee’s proposal to the independent board members James Noble, Staffan Lindstrand, Fred Wilkinson, Christine Rankin and Robin Evers of SEK 850,000, subject to (i) the board member’s acquisition of shares in Orexo for the entire part (after taxes) of such additional board fee as soon as possible following the annual general meeting’s resolution and the pay-out of the additional board fee, and (ii) the board member’s commitment not to sell the shares during the board member’s entire tenure on the Orexo board. The additional board fee is to be allocated as follows: SEK 450,000 to the chairman and SEK 100,000 to each of the other independent board members. Nomination committee The annual general meeting resolved to adopt procedures for the appointment of the nomination committee for the annual general meeting 2025 substantially in accordance with the same procedure as the preceding year. Approval of income statement and balance sheets, appropriation of the company’s profit or loss and discharge from liability The annual general meeting approved the income statement and the balance sheet for the parent company, as well as the consolidated income statement and the consolidated balance sheet for the financial year 2023. It was resolved, in accordance with the board of directors’ proposal, that there shall be no dividend for 2023 and that the results of the company shall be carried forward. The meeting also discharged the members of the board and the managing director from liability for the financial year 2023. Authorization to issue new shares The annual general meeting resolved to authorize the board of directors to resolve to issue new shares on one or several occasions until the next annual general meeting, with or without preferential rights for the shareholders, against cash payment or against payment through set-off or in kind, or otherwise on special conditions. However, such issue of shares must never result in the company’s issued share capital or the number of shares in the company at any time, being increased by more than a total of 20 per cent. The purpose of the authorization is to enable the board to make corporate acquisitions, product acquisitions or to enter into collaboration agreements, or to raise working capital or broaden the shareholder base. Authorization to repurchase and transfer shares The annual general meeting resolved to authorize the board of directors to resolve to repurchase, on one or several occasions until the next annual general meeting, as many own shares as may be purchased without the company’s holding at any time exceeding 10 per cent of the total number of shares in the company. Further, it was resolved to authorize the board of directors to resolve, on one or several occasions until the next annual general meeting, to transfer (sell) own shares. The purpose of the authorization to repurchase own shares is to promote efficient capital usage in the company, to provide flexibility as regards the company’s possibilities to distribute capital to its shareholders and for use in the context of the company’s incentive plans. The purpose of the authorization to transfer own shares is to enable the board to make corporate acquisitions, product acquisitions or enter into collaboration agreements, or to raise working capital or broaden the shareholder base or for use in the context of the company’s incentive plans. Long-term incentive program LTIP 2024 The annual general meeting resolved, in accordance with the board’s proposal, to adopt a new long-term incentive program for not more than 130 selected employees within the Orexo group, LTIP 2024. LTIP 2024 substantially corresponds with LTIP 2023, a performance based long-term incentive program adopted at the annual general meeting 2023. Long-term incentive program LTIP Stay-on 2024 The annual general meeting resolved, in accordance with the board’s proposal, to adopt a new long-term incentive program for approximately 13 Global Management Team employees and US Leadership Team employees within the Orexo group, LTIP Stay-on 2024. LTIP Stay-on 2024 substantially corresponds with LTIP Stay-on 2023, a performance based long-term incentive program adopted at the annual general meeting 2023. Complete proposals regarding the resolutions by the annual general meeting in accordance with the above together with the presentation from the managing director’s speech are available at Orexo’s website, www.orexo.com. The Board For further information please contact: Lena Wange, IR & Communications Director About Orexo Orexo is a Swedish pharmaceutical company with over 25 years of experience developing improved pharmaceuticals based on proprietary formulation technologies that meet large medical needs. On the US market, Orexo provides innovative treatment solutions for patients suffering from opioid use disorder and adjacent diseases. Products targeting other therapeutic areas are developed and commercialized worldwide with leading partners. Total net sales in 2023 amounted to SEK 639 million, and the number of employees to 116. Orexo is listed on Nasdaq Stockholm’s main list and is available as an ADR on OTCQX (ORXOY) in the US. For more information about Orexo please visit, www.orexo.com. You can also follow Orexo on X, LinkedIn, and YouTube. The information was sent for publication, through the agency of the contact person set out above, on April 26, 2024, at 5.30 pm CET. |
||||
2024-04-26 | Orexo | Kommuniké från Orexo AB:s årsstämma den 26 april 2024 | Pressreleaser | Download | Show Close |
|
||||
2024-04-25 | Penser Access by Carnegie | Penser Access by Carnegie: Orexo - Valutavinden har vänt, effekten begränsad i Q1 | Pressreleaser | Show Close |
|
||||
2024-04-17 | Orexo | Orexo extends patent protection for its nasal epinephrine powder product OX640 in the US | Pressreleaser | Download | Show Close |
|
||||
2024-04-17 | Orexo | Orexo förstärker patentskyddet i USA för OX640, ett pulverbaserat nasalt adrenalinläkemedel | Pressreleaser | Download | Show Close |
|
||||
2024-04-02 | Orexo | Orexo announces that the condition for early redemption of its existing bonds has been fulfilled | Pressreleaser | Download | Show Close |
|
||||
2024-04-02 | Orexo | Orexo meddelar att villkoret för förtida inlösen av sina befintliga obligationer har uppfyllts | Pressreleaser | Download | Show Close |
|
||||
2024-03-28 | Orexo | Orexo publicerar års- och hållbarhetsredovisning för 2023 | Rapporter | Download | Show Close |
|
||||
2024-03-28 | Orexo | Orexo publishes the Annual and Sustainability Report for 2023 | Rapporter | Download | Show Close |
|
||||
2024-03-21 | Penser Access by Carnegie | Penser Access by Carnegie: Orexo - Stärka finanser | Pressreleaser | Show Close |
|
||||
2024-03-15 | Orexo | Rättelse: Kallelse till årsstämma i Orexo | Pressreleaser | Show Close |
|
||||
2024-03-15 | Orexo | Correction: Notice of Annual General Meeting of Orexo | Pressreleaser | Show Close |
|
||||
2024-03-15 | Orexo | Kallelse till årsstämma i Orexo | Pressreleaser | Download | Show Close |
|
||||
2024-03-15 | Orexo | Notice of Annual General Meeting of Orexo | Pressreleaser | Download | Show Close |
|
||||
2024-03-13 | Orexo | Orexo har framgångsrikt emitterat seniora säkerställda sociala obligationer med rörlig ränta om SEK 500 m och offentliggör resultatet av återköpserbjudandet avseende sina befintliga obligationer | Pressreleaser | Download | Show Close |
|
||||
2024-03-13 | Orexo | Orexo successfully issues senior secured callable floating rate social bonds of SEK 500 m and announces results of the tender offer for its existing bonds | Pressreleaser | Download | Show Close |
|
||||
2024-03-08 | Orexo | Orexo överväger emission av seniora säkerställda sociala obligationer med rörlig ränta och offentliggör villkorat återköpserbjudande avseende sina befintliga obligationer | Pressreleaser | Download | Show Close |
|
||||
2024-03-08 | Orexo | Orexo contemplates issuance of senior secured callable floating rate social bonds and announces a conditional tender offer for its existing bonds | Pressreleaser | Download | Show Close |
|
||||
2024-03-08 | Orexo | Orexo stärker sitt hållbarhetsarbete genom att etablera ett socialt finansieringsramverk | Pressreleaser | Download | Show Close |
|
||||
2024-03-08 | Orexo | Orexo strengthens its sustainability work by establishing a social financing framework | Pressreleaser | Download | Show Close |
|
||||
2024-02-12 | Orexo | Orexo och Sobi avancerar förstudie med AmorphOX | Pressreleaser | Download | Show Close |
|
||||
2024-02-12 | Orexo | Orexo and Sobi agree to advance feasibility study with AmorphOX | Pressreleaser | Download | Show Close |
|
||||
2024-02-08 | Orexo | Orexo delårsrapport kv 4 2023, inkl. bokslutskommuniké | Rapporter | Download | Show Close |
|
||||
2024-02-08 | Orexo | Orexo Interim Report Q4 2023, incl. Full Year Report | Rapporter | Download | Show Close |
|
||||
2024-02-06 | Orexo | Orexos studieresultat för OX640 presenteras vid AAAAI:s Annual Meeting 2024 i Washington, DC, USA | Pressreleaser | Download | Show Close |
|
||||
2024-02-06 | Orexo | Orexo's OX640 development results to be presented at the 2024 AAAAI Annual Meeting in Washington, DC | Pressreleaser | Download | Show Close |
|
||||
2024-02-01 | Penser Access by Carnegie | Penser Access by Carnegie: Orexo - Motvind från valutan | Pressreleaser | Show Close |
|
||||
2023-11-29 | Penser Access | Penser Access: Interview with Orexo - Erik Penser Bank - Nov 29th 2023 | Pressreleaser | Show Close |
|
||||
2023-11-28 | Orexo | Orexo meddelar att FDA accepterat registreringsansökan för granskning av OX124, ett högdosläkemedel vid opioidöverdos | Pressreleaser | Download | Show Close |
|
||||
2023-11-28 | Orexo | Orexo announces FDA acceptance of New Drug Application filing for OX124, a high-dose rescue medication for opioid overdose | Pressreleaser | Download | Show Close |
|
||||
2023-11-06 | Penser Access | Penser Access: Intervju med Orexo - Erik Penser Bank - 6 november 2023 | Pressreleaser | Show Close |
|
||||
2023-11-03 | Penser Access | Penser Access: Går mot lönsamhet, men tillväxten dröjer - Orexo | Pressreleaser | Show Close |
|
||||
2023-11-02 | Orexo | Orexo Q3 2023 Interim Report | Rapporter | Download | Show Close |
|
||||
2023-11-02 | Orexo | Orexo delårsrapport kv 3 2023 | Rapporter | Download | Show Close |
|
||||
2023-10-27 | Orexo | Orexo meddelar förändringar i styrelsen | Pressreleaser | Download | Show Close |
|
||||
2023-10-27 | Orexo | Orexo announces changes in the company's Board of Directors | Pressreleaser | Download | Show Close |
|
||||
2023-10-26 | Orexo | Orexo's Nomination Committee for the Annual General Meeting 2024 | Pressreleaser | Download | Show Close |
|
||||
2023-10-26 | Orexo | Orexo:s valberedning inför årsstämman 2024 | Pressreleaser | Download | Show Close |
|
||||
2023-10-26 | Orexo | Kommuniké från Orexo:s extra bolagsstämma | Pressreleaser | Download | Show Close |
|
||||
2023-10-26 | Orexo | Report from Orexo's extraordinary general meeting | Pressreleaser | Download | Show Close |
|
||||
2023-10-11 | Orexo | Orexo announces data from the MODIA® study evaluating impact on use of illicit opioids | Pressreleaser | Download | Show Close |
|
||||
2023-10-11 | Orexo | Orexo offentliggör data från MODIA-studien som utvärderar effekten på användning av otillåtna opioider | Pressreleaser | Download | Show Close |
|
||||
2023-10-02 | Orexo | Kallelse till extra bolagsstämma i Orexo AB (publ) | Pressreleaser | Download | Show Close |
|
||||
2023-10-02 | Orexo | Notice of Extraordinary General Meeting in Orexo AB (publ) | Pressreleaser | Download | Show Close |
|
||||
2023-10-02 | Penser Access | Penser Access: Intervju med Orexo - Erik Penser Bank - 2 oktober 2023 | Pressreleaser | Show Close |
|
||||
2023-09-27 | Orexo | BioStock Investor Meeting: Orexo | Pressreleaser | Show Close |
|
||||
2023-09-27 | Orexo | BioStock Investor Meeting: Orexo | Pressreleaser | Show Close |
|
||||
2023-09-18 | Orexo | Orexo lämnar in registreringsansökan till FDA för OX124, ett högdos-läkemedel vid opioidöverdos | Pressreleaser | Download | Show Close |
|
||||
2023-09-18 | Orexo | Orexo submits New Drug Application to FDA for OX124, a high-dose rescue medication for opioid overdose | Pressreleaser | Download | Show Close |
|
||||
2023-09-05 | Orexo | Orexo deltar i Pareto Securities 14[th] Annual Healthcare Conference 2023 | Pressreleaser | Download | Show Close |
|
||||
2023-09-05 | Orexo | Orexo to participate in Pareto Securities' 14[th] Annual Healthcare Conference 2023 | Pressreleaser | Download | Show Close |
|
||||
2023-08-29 | Orexo | Orexo secures patent protection in the US for OX640, a nasal epinephrine powder product | Pressreleaser | Download | Show Close |
|
||||
2023-08-29 | Orexo | Orexo säkrar patentskydd i USA för OX640, ett pulverbaserat nasalt adrenalinläkemedel | Pressreleaser | Download | Show Close |
|
||||
2023-07-24 | Orexo | Orexo's patent win for ZUBSOLV[®] appealed | Pressreleaser | Download | Show Close |
|
||||
2023-07-24 | Orexo | Orexo:s seger i patenttvisten för ZUBSOLV[®] överklagas | Pressreleaser | Download | Show Close |
|
||||
2023-07-20 | Penser Access | Penser Access: Det har vänt, men värderingen släpar - Orexo | Pressreleaser | Show Close |
|
||||
2023-07-19 | Penser Access | Penser Access: Intervju med Orexo - Erik Penser Bank - 19 juli 2023 | Pressreleaser | Show Close |
|
||||
2023-07-18 | Orexo | Orexo delårsrapport kv 2 2023 | Rapporter | Download | Show Close |
|
||||
2023-07-18 | Orexo | Orexo Q2 2023 Interim Report | Rapporter | Download | Show Close |
|
||||
2023-07-03 | Penser Access | Penser Access: Intervju med Orexo - Erik Penser Bank - 3 juli 2023 | Pressreleaser | Show Close |
|
||||
2023-07-03 | Penser Access | Penser Access: Segrar i patenttvist - Orexo | Pressreleaser | Show Close |
|
||||
2023-07-01 | Orexo | Orexo wins patent litigation for ZUBSOLV® in the US | Pressreleaser | Download | Show Close |
|
||||
2023-07-01 | Orexo | Orexo vinner patenttvist för ZUBSOLV® i USA | Pressreleaser | Download | Show Close |
|
||||
2023-05-22 | Penser Access | Penser Access: Krisvärdering inför viktiga besked - Orexo | Pressreleaser | Show Close |
|
||||
2023-05-03 | Penser Access | Penser Access: Intervju med Orexo - Erik Penser Bank - 2 maj 2023 | Pressreleaser | Show Close |
|